Discovery of novel oral protein synthesis inhibitors of mycobacterium tuberculosis that target leucyl-tRNA synthetase

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 6271-6280

  Palencia, Andrés ^a   Li, Xianfeng ^b   Bu, Wei ^b   Choi, Wai ^b   Ding, Charles Z ^b   Easom, Eric E ^b   Feng, Lisa ^b   Hernandez, Vincent ^b   Houston, Paul ^b   Liu, Liang ^b   Meewan, Maliwan ^b   Mohan, Manisha ^b   Rock, Fernando L ^b   Sexton, Holly ^b   Zhang, Suoming ^b   Zhou, Yasheen ^b   Wan, Baojie ^c   Wang, Yuehong ^c   Franzblau, Scott G ^c   Woolhiser, Lisa ^d   Gruppo, Veronica ^d   Lenaerts, Anne J ^d   O'Malley, Theresa ^e   Parish, Tanya ^e   Cooper, Christopher B ^f   Waters, M Gerard ^f   Ma, Zhenkun ^f   Ioerger, Thomas R ^g   Sacchettini, James C ^g   Rullas, Joaquín ^h   Angulo Barturen, Iñigo ^h   Pérez Herrán, Esther ^h   Mendoza, Alfonso ^h   Barros, David ^h   Cusack, Stephen ^a   Plattner, Jacob J ^b   Alley, M R K ^b   more..

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^f GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^g TEXAS A AND M UNIVERSITY   (United States)

^h GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOMETHYL BENZOXABOROLE DERIVATIVE; AN2679; AN3016; AN3017; CHLORAMPHENICOL; DOXYCYCLINE; EPETRABOROLE; ERYTHROMYCIN; ISONIAZID; LEUCINE TRANSFER RNA LIGASE; LIGASE INHIBITOR; LINEZOLID; MOXIFLOXACIN; ORGANOBORON DERIVATIVE; PRETOMANID; PROTEIN SYNTHESIS INHIBITOR; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTAGONIST POTENCY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL TUBERCULOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STRUCTURE ACTIVITY RELATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; WHOLE CELL; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; INBRED MOUSE STRAIN; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM SMEGMATIS; ORAL DRUG ADMINISTRATION; PRECLINICAL STUDY; PROCEDURES; TUBERCULOSIS; VERO CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LEUCINE-TRNA LIGASE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PROTEIN SYNTHESIS INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS; VERO CELLS;

EID: 84992694359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01339-16     Document Type: Article

References (37)

1. Woese CR, Olsen GJ, Ibba M, Soll D. 2000. Aminoacyl-tRNA synthetases, the genetic code, and the evolutionary process. Microbiol Mol Biol Rev 64:202-236. http://dx.doi.org/10.1128/MMBR.64.1.202-236.2000.
2. Vondenhoff GH, Van Aerschot A. 2011. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem 46:5227-5236. http: //dx.doi.org/10.1016/j.ejmech.2011.08.049.
3. Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. 1985. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 27:495-498. http: //dx.doi.org/10.1128/AAC.27.4.495.
4. Sassanfar M, Kranz JE, Gallant P, Schimmel P, Shiba K. 1996. A eubacterial Mycobacterium tuberculosis tRNA synthetase is eukaryote-like and resistant to a eubacterial-specific antisynthetase drug. Biochemistry 35:9995-10003. http://dx.doi.org/10.1021/bi9603027.
5. Cusack S, Yaremchuk A, Tukalo M. 2000. The 2 A crystal structure of leucyl-tRNA synthetase and its complex with a leucyl-adenylate analogue. EMBO J 19:2351-2361. http://dx.doi.org/10.1093/emboj/19.10.2351.
6. Englisch S, Englisch U, von der Haar F, Cramer F. 1986. The proofreading of hydroxy analogues of leucine and isoleucine by leucyl-tRNA synthetases from E. coli and yeast. Nucleic Acids Res 14:7529-7539. http: //dx.doi.org/10.1093/nar/14.19.7529.
7. Lincecum TL, Jr, Tukalo M, Yaremchuk A, Mursinna RS, Williams AM, Sproat BS, Van Den Eynde W, Link A, Van Calenbergh S, Grotli M, Martinis SA, Cusack S. 2003. Structural and mechanistic basis of pre- and posttransfer editing by leucyl-tRNA synthetase. Mol Cell 11:951-963. http://dx.doi.org/10.1016/S1097-2765(03)00098-4.
8. Palencia A, Crepin T, Vu MT, Lincecum TL, Jr, Martinis SA, Cusack S. 2012. Structural dynamics of the aminoacylation and proofreading functional cycle of bacterial leucyl-tRNA synthetase. Nat Struct Mol Biol 19: 677-684. http://dx.doi.org/10.1038/nsmb.2317.
9. Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T, Zhou H, Zhang YK, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MR. 2007. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316:1759-1761. http://dx.doi.org/10.1126/science.1142189.
10. Kabsch W. 1993. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26:795-800. http://dx.doi.org/10.1107/S0021889893005588.
11. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763.
12. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. 2005. Likelihood- enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61:458-464. http://dx.doi.org/10.1107/S0907444905001617.
13. Liu Y, Liao J, Zhu B, Wang ED, Ding J. 2006. Crystal structures of the editing domain of Escherichia coli leucyl-tRNA synthetase and its complexes with Met and Ile reveal a lock-and-key mechanism for amino acid discrimination. Biochem J 394:399-407. http://dx.doi.org/10 .1042/BJ20051249.
14. Perrakis A, Morris R, Lamzin VS. 1999. Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6:458-463. http://dx.doi.org/10.1038/8263.
15. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. http://dx.doi .org/10.1107/S0907444904019158.
16. Chen VB, Arendall WB, III, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12-21. http://dx.doi.org/10.1107 /S0907444909042073.
17. Collins L, Franzblau SG. 1997. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41:1004-1009.
18. Ollinger J, Bailey MA, Moraski GC, Casey A, Florio S, Alling T, Miller MJ, Parish T. 2013. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS One 8:e60531. http://dx.doi.org/10.1371/journal.pone.0060531.
19. Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE, III, Sherman DR, Parish T, Sacchettini JC. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8:e75245. http://dx.doi.org/10.1371/journal.pone.0075245.
20. Sirgel FA, Wiid IJ, van Helden PD. 2009. Measuring minimum inhibitory concentrations in mycobacteria. Methods Mol Biol 465:173-186. http://dx.doi.org/10.1007/978-1-59745-207-6-11.
21. Hernandez V, Crepin T, Palencia A, Cusack S, Akama T, Baker SJ, Bu W, Feng L, Freund YR, Liu L, Meewan M, Mohan M, Mao W, Rock FL, Sexton H, Sheoran A, Zhang Y, Zhang Y-K, Zhou Y, Nieman JA, Anugula MR, Keramane EM, Savariraj K, Reddy DS, Sharma R, Subedi R, Singh R, O'Leary A, Simon NL, De Marsh PL, Mushtaq S, Warner M, Livermore DM, Alley MR, Plattner JJ. 2013. Discovery of a novel class of boron-based antibacterials with activity against Gram-negative bacteria. Antimicrob Agents Chemother 57:1394-1403. http://dx.doi.org/10.1128 /AAC.02058-12.
22. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49: 2294-2301. http://dx.doi.org/10.1128/AAC.49.6.2294-2301.2005.
23. Rullas J, Garcia JI, Beltran M, Cardona PJ, Caceres N, Garcia-Bustos JF, Angulo-Barturen I. 2010. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 54: 2262-2264. http://dx.doi.org/10.1128/AAC.01423-09.
24. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. http://dx.doi.org/10.1038/35016103.
25. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. 2003. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 47:783-785. http: //dx.doi.org/10.1128/AAC.47.2.783-785.2003.
26. Seiradake E, Mao W, Hernandez V, Baker SJ, Plattner JJ, Alley MR, Cusack S. 2009. Crystal structures of the human and fungal cytosolic leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles. J Mol Biol 390:196-207. http://dx .doi.org/10.1016/j.jmb.2009.04.073.
27. O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. 2015. Bacterial resistance to leucyltRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother 59: 289-298. http://dx.doi.org/10.1128/AAC.03774-14.
28. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis.NEngl J Med 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
29. Hamasaki K, Rando RR. 1997. Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Biochemistry 36:12323-12328. http: //dx.doi.org/10.1021/bi970962r.
30. Benne R, Sloof P. 1987. Evolution of the mitochondrial protein synthetic machinery. Biosystems 21:51-68. http://dx.doi.org/10.1016 /0303-2647(87)90006-2.
31. Lue SW, Kelley SO. 2005. An aminoacyl-tRNA synthetase with a defunct editing site. Biochemistry 44:3010-3016. http://dx.doi.org/10 .1021/bi047901v.
32. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, van Soolingen D, Bakker-Woudenberg IA. 2010. Timekill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 65:2582-2589. http://dx.doi.org/10.1093/jac/dkq374.
33. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51:576-582. http: //dx.doi.org/10.1128/AAC.00414-06.
34. British Medical Journal. 1948. Streptomycin treatment of pulmonary tuberculosis. Br Med J ii:769-782.
35. Graessle OE, Pietrowski JJ. 1949. The in vitro effect of para-aminosalicylic acid (PAS) in preventing acquired resistance to streptomycin by Mycobacterium tuberculosis. J Bacteriol 57:459-464.
36. Nagley MM. 1950. The combined use of para-aminosalicylic acid (PAS) and streptomycin in pulmonary tuberculosis. Tubercle 31:151-155. http: //dx.doi.org/10.1016/S0041-3879(50)80136-8.
37. Palminteri R, Sassella D. 1979. Double-blind multicenter trial of a rifampicin-trimethoprim combination and rifampicin alone in urinary tract infections. Chemotherapy 25:181-188. http://dx.doi.org/10 .1159/000237838.